ResearchMoz added Latest Research Report titled " PharmaPoint: Parkinsons Disease - 5EU Drug Forecast and Market Analysis to 2022 " to it's Large Report database.
PharmaPoint: Parkinsons Disease - 5EU Drug Forecast and Market Analysis to 2022
Summary
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197509
Although France has a lower-than-average rate of generic substitution compared with other parts of Europe, increasing pressures from its aging population and increased disease burden are forcing governments to institute cost-saving measures. The market leader therapies in Germany are all no longer patent protected and include the class of oral dopamine agonists. While the overall pharmaceutical market in Italy is shrinking, the medical device market in Italy is growing. This market growth will be driven by six new product launches, and by an aging population, resulting in an increased prevalence of Parkinsons disease in Spain. Population growth and the aging population will continue to build steady growth in the UK Parkinsons disease market and six additional product launches, including the introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 11
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 16
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 22
3.1.3 Prognosis 24
3.1.4 Quality of Life 25
3.2 Symptoms 25
4 Disease Management 27
4.1 Overview 27
4.1.1 Diagnosis - The UK Brain Bank Criteria 27
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 28
4.2 Treatment Synopsis 30
4.2.1 Dopaminergic Therapy Classes 31
4.2.2 Treatment of Parkinsons disease by Stage 33
4.2.3 Other Treatment Options 36
4.3 Parkinsons Disease Assessment Scales 36
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 37
4.3.2 Hoehn and Yahr Clinical Staging 39
4.3.3 Other Clinical Assessments 40
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
PharmaPoint: Parkinsons Disease - 5EU Drug Forecast and Market Analysis to 2022
Summary
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197509
Although France has a lower-than-average rate of generic substitution compared with other parts of Europe, increasing pressures from its aging population and increased disease burden are forcing governments to institute cost-saving measures. The market leader therapies in Germany are all no longer patent protected and include the class of oral dopamine agonists. While the overall pharmaceutical market in Italy is shrinking, the medical device market in Italy is growing. This market growth will be driven by six new product launches, and by an aging population, resulting in an increased prevalence of Parkinsons disease in Spain. Population growth and the aging population will continue to build steady growth in the UK Parkinsons disease market and six additional product launches, including the introduction of A2A antagonists in 2019, will bring in an extra $24.7m in sales in 2022.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 11
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 16
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 22
3.1.3 Prognosis 24
3.1.4 Quality of Life 25
3.2 Symptoms 25
4 Disease Management 27
4.1 Overview 27
4.1.1 Diagnosis - The UK Brain Bank Criteria 27
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 28
4.2 Treatment Synopsis 30
4.2.1 Dopaminergic Therapy Classes 31
4.2.2 Treatment of Parkinsons disease by Stage 33
4.2.3 Other Treatment Options 36
4.3 Parkinsons Disease Assessment Scales 36
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 37
4.3.2 Hoehn and Yahr Clinical Staging 39
4.3.3 Other Clinical Assessments 40
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment